We conducted a prospective trial to determine whether a formal, integrated pharmaceutical care plan can enhance patient acceptance and compliance with colestipol therapy and improve outcomes.
Forty patients with hypercholesterolemia were equally divided and assigned to either a usual care or pharmaceutical care group.
In the pharmaceutical care group compared with the usual care group, after 52 weeks, colestipol therapy resulted in a greater reduction in total cholesterol (12.5% vs 7.3%), low-density lipoprotein cholesterol (LDL-C ; 16% vs 9.4%), and LDL-C : high-density lipoprotein cholesterol (HDL-C) ratio (24.4% vs 12.2%, p<0.05).
The percentage of patients who achieved their LDL-C goal at week 52 was much greater in the pharmaceutical care group (29.4%) than in the usual care group (5.0%, p<0.05).
Comanagement by a physician and a pharmacist of hypercholesterolemic veterans treated with colestipol can enhance patient acceptance of the drug, LDL-C reduction, and achievement of therapeutic goals.
Mots-clés Pascal : Colestipol, Hypolipémiant, Vieillard, Homme, Hypercholestérolémie, Chimiothérapie, Traitement, Efficacité traitement, Prospective, Observance médicamenteuse, Pharmacien, Activité professionnelle, Voie orale, Relation médecin malade, Lipide, Métabolisme pathologie, Dyslipémie, Hyperlipoprotéinémie, Soin pharmaceutique, Suivi thérapeutique médicamenteux
Mots-clés Pascal anglais : Colestipol, Antilipemic agent, Elderly, Human, Hypercholesterolemia, Chemotherapy, Treatment, Treatment efficiency, Prospective, Drug compliance, Chemist, Professional activity, Oral administration, Physician patient relation, Lipids, Metabolic diseases, Dyslipemia, Hyperlipoproteinemia, Pharmaceutical care, Therapeutic drug monitoring
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0339512
Code Inist : 002B02N. Création : 12/09/1997.